FrancophonIA/ELRC3.0 huggingface dataset:
English: PACKAGE LEAFLET: Rheumocam 0.5 mg/ml oral suspension for cats
Estonian: PAKENDI INFOLEHT Rheumocam 0,5 mg/ml suukaudne suspensioon kassidele
English: Meloxicam 5 mg Ethanol (96%) 159.8 mg Clear, yellow solution.
Estonian: Meloksikaam 5 mg Etanool (96%) 159.8 mg Selge kollane lahus.
English: Meloxicam 20 mg/ml, Ethanol (96 percent) 159.8 mg/ml.
Estonian: Meloksikaam 20 mg/ml Etanool (96%) 159.8 mg/ml
English: Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.05 mg meloxicam/kg body weight (0.1 ml /kg).
Estonian: Ravi jätkamiseks tuleb manustada Rheumocami suukaudselt üks kord päevas (24tunniste vahedega) säilitava annusena 0,05 mg meloksikaami 1 kg kehamassi kohta (0.1 ml /kg).
English: Rheumocam 5 mg/ml solution for injection for dogs and cats
Estonian: Rheumocam 5 mg/ml süstelahus koertele ja kassidele
English: The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reactions) - common (more than 1 but less than 10 animals in 100 animals treated)
Estonian: Kõrvaltoimete esinemissagedus on defineeritud järgnevalt: - väga sage ( kõrvaltoime(d) ilmnes(id) rohkem kui 1-l loomal 10-st ravitud loomast) - sage (rohkem kui 1-l, kuid vähem kui 10-l loomal 100-st ravitud loomast)
English: PACKAGE LEAFLET: Rheumocam 5 mg/ml solution for injection for cattle and pigs
Estonian: PAKENDI INFOLEHT Rheumocam 5 mg/ml süstelahus veistele ja sigadele
English: Initial treatment is a single oral dose of 0.2 mg meloxicam/kg body weight (0.4 ml/kg) on the first day.
Estonian: Algseks raviks on esimesel päeval ühekordne suukaudne annus 0,2 mg meloksikaami 1 kg kehamassi kohta (0.04 ml /kg).
English: Rheumocam 0.5 mg/ml oral suspension for cats.
Estonian: Rheumocam 0,5 mg/ml suukaudne suspensioon kassidele
English: {Label for 20 ml bottles}
Estonian: 20 ml pudeli etikett
English: Rheumocam 0.5 mg/ml oral suspension for cats meloxicam
Estonian: Rheumocam 0,5 mg/ml suukaudne suspensioon kassidele meloksikaam
English: - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Estonian: - harv (rohkem kui 1-l, kuid vähem kui 10-l loomal 10 000-st ravitud loomast) - väga harv (vähem kui 1-l loomal 10 000-st ravitud loomast, kaasaarvatud üksikjuhud).
English: IE - Ireland Tel: + 353 91 841788
Estonian: Co. Galway IE - Ireland Tel: + 353 91 841788
English: In dogs, meloxicam is eliminated with a half-life of 24 hours.
Estonian: Koertel väljub koos poolväärtusaeg on 24 tundi.
English: {Carton for 100 ml or 250 ml bottle}
Estonian: 100 ml või 250 ml pudeli karp
English: Pharmacotherapeutic group: Anti-inflammatory and Anti-rheumatic products, Non-steroids (oxicams).
Estonian: Farmakoterapeutiline rühm: mittesteroidsed põletiku- ja reumavastased ained (oksikaamid).
English: Rheumocam 5 mg/ml solution for injection for cattle and pigs
Estonian: Rheumocam 5 mg/ml süstelahus veistele ja sigadele
English: Cattle: Meat and offal: 15 days
Estonian: Veistel: lihale ja söödavatele kudedele: 15 päeva
English: Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.
Estonian: Kasutamata jäänud ravimeid ega jäätmematerjali ei tohi ära visata kanalisatsiooni kaudu ega koos majapidamisprügiga, vaid tuleb hävitada vastavalt kohalikule seadusandlusele.
English: 60) blister packs with a 20 micron foil.
Estonian: 60), blisterpakendites, millel on 20 mikronit Foil Pakendi suurused: 20 tablett, 100 tablett Kõik pakendi suurused ei pruugi olla müügil.
English: In cats, meloxicam is predominantly found in plasma and is also a major biliary excretion product whereas urine contains only traces of the parent compound.
Estonian: Kassidel leidub meloksikaami valdavalt plasmas ja see ka eritub peamiselt sapiga, uriin sisaldab ainult jäljed lähteaine.
English: People with known hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) should avoid contact with the veterinary medicinal product.
Estonian: Inimesed, kes on mittesteroidsete põletikuvastaste ravimite suhtes ülitundlikud, peaksid kokkupuudet veterinaarravimiga vältima.
English: In very rare cases elevated liver enzymes have been reported.
Estonian: Väga harvadel juhtudel maksaensüümide tekkest.
English: Chanelle Pharmaceuticals Manufacturing Ltd., Loughrea, Co. Galway,
Estonian: Chanelle Pharmaceuticals Manufacturing Ltd., Loughrea,
English: Muscle Liver Kidney
Estonian: Sidrunhappe monohüdraat Sorbitoolilahus
English: Approximately 75 % of the administered dose is eliminated via faeces and the remainder via urine.
Estonian: Umbes 75% manustatud annusest roojaga ja ülejäänud osa uriiniga.
English: Rheumocam 5 mg/ml solution for injection for dogs and cats Meloxicam
Estonian: Rheumocam 5 mg/ml süstelahus koertele ja kassidele Meloksikaam
English: Cardboard box containing 1 colourless glass injection vial of 20 ml, 50 ml or 100 ml.
Estonian: Pappkarp 1 värvitust klaasist süsteviaaliga, iga viaal sisaldab 20 ml, 50 ml või 100 ml.
English: Pale-yellow, single-scored, chewable tablets.
Estonian: Laktoosmonohüdraat, Mikrokristalne tselluloos, Naatriumtsitraat, Krospovidoon, Talk,
English: Meloxicam: 5 mg/ml Ethanol (96%): 159.8 mg/ml
Estonian: Meloksikaam 5 mg/ml Etanool (96%) 159.8 mg/ml
English: In very rare cases, haemorrhagic diarrhoea, haematemesis, and gastrointestinal ulceration have been reported.These side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment, but in very rare cases may be serious or fatal.
Estonian: Koertel tekivad need kõrvaltoimed tavaliselt esimesel ravinädalal, on enamasti mööduva iseloomuga ja kaovad pärast ravi lõppu, kuid väga harva võivad olla ka rasked või lõppeda surmaga.
English: Single subcutaneous or intravenous injection at a dosage of 0.5 mg meloxicam/kg body weight (i.e. 10 ml/100 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate.
Estonian: Manustada subkutaanselt või intravenoosselt üks kord annuses 0,5 mg meloksikaami 1 kg kehamassi kohta (s.t 10 ml 100 kg kehamassi kohta), vajaduse korral kombineeritult antibiootikumiraviga või suukaudse rehüdratsioonraviga.
English: Withdrawal period Cattle: meat and offal: 15 days.
Estonian: Keeluaeg Veistel: lihale ja söödavatele kudedele: 15 päeva
English: Talc
Estonian: karp
English: {Label for 100 ml and 250 ml bottles}
Estonian: 100 ml ja 250 ml pudeli etikett
English: Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs.
Estonian: Põletiku ja valu leevendamine ägedate või krooniliste lihas-skeleti kahjustuste korral koertel.
English: The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reactions) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated)
Estonian: Kõrvaltoimete esinemissagedus on defineeritud järgnevalt: - väga sage ( kõrvaltoime(d) ilmnes(id) rohkem kui 1-l loomal 10-st ravitud loomast) - sage (rohkem kui 1-l, kuid vähem kui 10-l loomal 100-st ravitud loomast) - aeg-ajalt (rohkem kui 1-l, kuid vähem kui 10-l loomal 1000-st ravitud loomast)
English: After two intramuscular doses of 0.4 mg meloxicam/kg, a Cmax value of 1.9 μg/ml was reached after 1 hour in pigs.
Estonian: Pärast kaht intramuskulaarset annust 0,4 mg meloksikaami/kg saavutati sigadel C
English: {Carton for 20 ml, 50 ml, 100 ml and 250 ml}
Estonian: 20 ml, 50 ml, 100 ml või 250 ml pudeli karp
English: Meloxicam:
Estonian: Meloksikaam:
English: Rheumocam 5 mg/ml Solution for injection for Cattle and Pigs Meloxicam
Estonian: Rheumocam 5 mg/ml süstelahus veistele ja sigadele Meloksikaam
English: Chanelle Pharmaceuticals Manufacturing Ltd., Loughrea, Co. Galway, Ireland and
Estonian: Partii vabastamise eest vastutav tootja Chanelle Pharmaceuticals Manufacturing Ltd. Loughrea, Co. Galway, Iirimaa ja
English: Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.1 mg meloxicam/kg body weight.
Estonian: Ravi jätkamiseks tuleb manustada Rheumocami suu kaudu üks kord päevas (24-tunniste vahedega) säilitava annusena 0,1 mg meloksikaami 1 kg kehamassi kohta.
English: {Carton for 10 ml, 20 ml and 100 ml vial}
Estonian: 10 ml, 20 ml või 100 ml pudeli karp
English: For the relief of post operative pain associated with minor soft tissue such as castration.
Estonian: Pehmte kudede väiksemate operatsioonidega, näiteks kastreerimisega kaasneva operatsioonijärgse valu leevendamine.
English: Meat and offal: 15 days.
Estonian: Lihale ja söödavatele kudedele: 15 päeva
English: Post operative pain associated with minor soft tissue surgery such as castration.
Estonian: Pehmete kudede väiksemate operatsioonidega, näiteks kastreerimisega kaasnev operatsioonijärgne valu leevendamine.
English: MRL
Estonian: i.m.
English: Marketing authorisation holder:
Estonian: Kõrvaltoimete esinemissagedus on defineeritud järgnevalt:
English: Typical adverse drug reactions of non-steroidal anti-inflammatory drugs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported.
Estonian: Aeg-ajalt on teatatud tüüpilistest mittesteroidsete põletikuvastaste ravimite kõrvaltoimetest, nt isutus, oksendamine, kõhulahtisus, veri roojas, letargia ja neerupuudulikkus.
English: Cardboard box containing one colourless glass injection vial of 20 ml, 50 ml, 100 ml or 250 ml.
Estonian: Pappkarp 1 värvitust klaasist 20 ml, 50 ml, 100 ml või 250 ml süsteviaaliga.
English: Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of increased renal toxicity.
Estonian: Potentsiaalselt suurema nefrotoksilisuse tõttu vältida ravimi kasutamist dehüdreerunud, hüpovoleemilisel või hüpotensiivsel loomal.
English: {Label for 50 ml, 100 ml and 250 ml}
Estonian: 50 ml, 100 ml ja 250 ml pudeli etikett
English: Contraindications”.
Estonian: sünteesi.
English: Special precautions to be taken by the person administering the veterinary medicinal product to animals.
Estonian: Ettevaatusabinõud veterinaarravimit loomale manustavale isikule Juhuslik süstimine iseendale võib tekitada valu.
English: Glucose monohydrate
Estonian: Glükoos monohüdraat
English: 1 pre-filled syringe + 1 injection needle
Estonian: Infusioonilahuse kontsentraat ja lahusti eeltäidetud süstal + 1 nõel süstimiseks eeltäidetud süstalt + 4 nõela süstimiseks
English: It must be taken with at least two other antiviral medicines.
Estonian: Seda tuleb võtta koos vähemalt kahe muu viiruseravimiga.
English: Because the medicine can cause serious rash, treatment starts with 200 mg once a day for two weeks, before increasing the dose to the standard dose of 200 mg twice a day.
Estonian: Et ravim võib tekitada raske lööbe, alustatakse ravi esialgu annusega 200 mg üks kord ööpäevas kahe nädala jooksul ja seejärel suurendatakse annus tavaannuseni 200 mg kaks korda ööpäevas.
English: The full EPAR for Nevirapine Teva can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Nevirapine Teva kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The European Commission granted a marketing authorisation valid throughout the EU for Nevirapine Teva on 30 November 2009.
Estonian: Euroopa Komisjon andis Nevirapine Teva müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 30. novembril 2009.
English: Nevirapine Teva does not cure HIV-1 infection or AIDS, but it may delay the damage to the immune system and the development of infections and diseases associated with AIDS.
Estonian: Nevirapine Teva ei ravi HIV-nakkust ega AIDS-i välja, kuid võib immuunsüsteemi kahjustumist ning AIDS-iga seotud nakkuste ja haiguste tekkimist edasi lükata.
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom increased to the full twice-daily dose until any rash has cleared.
Estonian: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
English: If the patient cannot switch to the twice-daily dose within four weeks of starting Nevirapine Teva, alternative treatments should be sought.
Estonian: Kui patsient ei saa hakata kasutama tavaannust nelja nädala jooksul alates ravi algusest Nevirapine Tevaga, tuleb leida muid ravivõimalusi.
English: Nevirapine Teva nevirapine
Estonian: Nevirapine Teva nevirapiin
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Nevirapine Teva.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: For more information about treatment with Nevirapine Teva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Nevirapine Tevaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: The Committee recommended that Nevirapine Teva be given marketing authorisation.
Estonian: Komitee soovitas anda Nevirapine Teva müügiloa.
English: This is a summary of the European public assessment report (EPAR) for Nevirapine Teva.
Estonian: See on Nevirapine Teva Euroopa avaliku hindamisaruande kokkuvõte.
English: Other information about Nevirapine Teva
Estonian: Muu teave Nevirapine Teva kohta
English: Therefore, the CHMP's view was that, as for Viramune, the benefit outweighs the identified risk.
Estonian: Seetõttu arvas inimravimite komitee, et nagu ka Viramune korral, ületab ravimi kasulikkus sellega kaasnevad riskid.
English: By blocking this enzyme, Nevirapine Teva, taken in combination with other antiviral medicines, reduces the amount of HIV-1 in the blood and keeps it at a low level.
Estonian: Blokeerides selle ensüümi, vähendab koos teiste viiruseravimitega manustatav Nevirapine Teva HIVi kogust veres ja hoiab selle sisalduse väikese.
English: Because Nevirapine Teva is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as the reference medicine.
Estonian: Et Nevirapine Teva on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: Treatment with Nevirapine Teva should be given by a doctor who has experience in the treatment of HIV infection.
Estonian: Ravi Nevirapine Tevaga peab läbi viima HIV-nakkuse ravis kogenud arst.
English: The CHMP concluded that, in accordance with EU requirements, Nevirapine Teva has been shown to have comparable quality and to be bioequivalent to Viramune.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Nevirapine Teva võrdväärne kvaliteet ja bioekvivalentsus ravimiga Viramune.
English: Why has Nevirapine Teva been approved?
Estonian: Miks Nevirapine Teva heaks kiideti?
English: This means that Nevirapine Teva is similar to a ‘reference medicine' already authorised in the European Union (EU) called Viramune.
Estonian: See tähendab, et Nevirapine Teva on sarnane võrdlusravimiga Viramune, millel juba on Euroopa Liidus müügiluba.
English: What is Nevirapine Teva?
Estonian: Mis on Nevirapine Teva?
English: Because Nevirapine Teva is a generic medicine, studies have been limited to tests to determine that it is bioequivalent to the reference medicine, Viramune.
Estonian: Et Nevirapine Teva on geneeriline ravim, piirdusid uuringud katsetega, milles näidati Nevirapine Teva bioekvivalentsust võrdlusravimiga Viramune.
English: Nevirapine Teva is a medicine that contains the active substance nevirapine.
Estonian: Nevirapine Teva on ravim, mis sisaldab toimeainena nevirapiini.
English: The active substance in Nevirapine Teva, nevirapine, is a non-nucleoside reverse transcriptase inhibitor (NNRTI).
Estonian: Nevirapine Teva toimeaine nevirapiin on mittenukleosiidne pöördtranskriptaasi inhibiitor (NNRTI), mis blokeerib ensüümi pöördtranskriptaasi toime.
English: Nevirapine Teva is a ‘generic medicine'.
Estonian: Nevirapine Teva on geneeriline ravim.
English: It blocks the activity of reverse transcriptase, an enzyme produced by HIV-1 that allows it to infect cells in the body and make more viruses.
Estonian: See HIV-1 tekitatav ensüüm võimaldab viirusel nakatunud rakkudes paljuneda.
English: How has Nevirapine Teva been studied?
Estonian: Kuidas Nevirapine Tevat uuriti?
English: What are the benefits and risks of Nevirapine Teva?
Estonian: Milles seisneb Nevirapine Teva kasulikkus ja mis riskid ravimiga kaasnevad?
English: Nevirapine Teva is never taken on its own.
Estonian: Nevirapine Tevat ei tohi mitte kunagi kasutada ainsa ravimina.
English: Nevirapine Teva is an antiviral medicine.
Estonian: Nevirapine Teva on viiruseravim.
English: How is Nevirapine Teva used?
Estonian: Kuidas Nevirapine Tevat kasutatakse?
English: The dose should not be
Estonian: kogu lööve on kadunud.
English: What is Nevirapine Teva used for?
Estonian: Milleks Nevirapine Tevat kasutatakse?
English: Package Leaflet: Information for the user
Estonian: Pakendi Infoleht: teave kasutajale
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 23.08.2012
Estonian: ESMASE MÜÜGILOA VÄLJASTAMISE/MÜÜGILOA UUENDAMISE KUUPÄEV Müügiloa esmase väljastamise kuupäev: 23.08.2012
English: - A kidney function disorder called Fanconi syndrome (will normally be determined by your doctor with certain urine tests).
Estonian: - Neerufunktsiooni häire, mida kutsutakse Fanconi sündroomiks (tavaliselt tuvastab teie arst selle teatud uriinianalüüsidega).
English: Date of latest renewal: 24.05.2017
Estonian: Müügiloa viimase uuendamise kuupäev: 24.05.2017
English: B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Estonian: B. HANKE - JA KASUTUSTINGIMUSED VÕI PIIRANGUD Piiratud tingimustel väljastatav retseptiravim (vt I lisa: Ravimi omaduste kokkuvõte, lõik 4.2).
English: Tell your doctor if you are or think that you may be pregnant.
Estonian: Informeerige arsti juhul, kui te olete rase või arvate, et olete rasestunud.
English: Can't be sold separately.
Estonian: Mitmikpakendi osa, ei müüda eraldi.
English: Estrada do Rio da Mó , nº 8, 8-A e 8-B Fervença, Terrugem SNT, 2705-906 Portugal
Estonian: Hikma Farmacêutica S.A. Estrada do Rio da Mó , nº 8, 8-A e 8-B Fervença, Terrugem SNT, 2705-906 Portugal
English: Tell your doctor about any of the following serious side effects straight away:
Estonian: Rääkige oma arstile mis tahes järgneva tõsise kõrvaltoime esinemisest otsekohe.
English: 1 vial of 5 ml 4 vials of 5 ml 10 vials of 5 ml
Estonian: 1 viaal 5 ml 4 viaali 5 ml 10 viaali 5 ml
English: - if you are allergic to zoledronic acid, another bisphosphonate (the group of substances to which zoledronic acid belongs), or any of the other ingredients of this medicine (listed in section 6).
Estonian: - kui olete zoledroonhappe, mõne teise bisfosfonaadi (ravimigrupp, millesse zoledroonhape kuulub) või selle ravimi mis tahes koostisosade (loetletud lõigus 6) suhtes allergiline.
English: 1 Adverse events occurring with frequencies < 5% were medically assessed and it was shown that these cases are consistent with the well established safety profile of zoledronic acid (see section 4.8)
Estonian: 1 Kõrvaltoimed esinemissagedusega < 5% olid meditsiiniliselt hinnatud ning näidatud, et need juhtumid on kooskõlas zoledroonhappe ohutusandmetega (vt lõik 4.8).
English: For storage conditions after dilution of the medicinal product, see section 6.3.
Estonian: Säilitamistingimised pärast ravimpreparaadi lahjendamist vt lõik 6.3.
English: Additional information on handling of Zoledronic acid Mylan, including guidance on preparation of reduced doses, is provided in section 4.2.
Estonian: Lisainfo Zoledronic acid Mylan'i käsitsemise kohta, sealhulgas juhend vähendatud annusega lahuse valmistamiseks, on esitatud lõigus 4.2.
English: Zoledronic acid Mylan is supplied as packs containing 1, 4 or 10 vials or as multipacks comprising 4 packs, each containing 1 vial.
Estonian: Zoledronic acid Mylan turustatakse pakendites, mis sisaldavad 1, 4 või 10 viaali või mitmikpakendis, mis sisaldab 4 pakendit, igas 1 viaal.
English: - To reduce the amount of calcium in the blood in adult patients where it is too high due to the presence of a tumour.
Estonian: - Kaltsiumisisalduse vähendamiseks veres täiskasvanud patsientidel juhtudel, kui see on kasvaja tõttu liiga kõrge.
English: While being treated with Zoledronic acid Mylan, you should maintain good oral hygiene (including regular teeth brushing) and receive routine dental check-ups.
Estonian: Zoledronic acid Mylan'ga ravi ajal tuleb teil säilitada korralikku suuhügieeni (sealhulgas regulaarne hammaste pesemine) ning käia regulaarselt hammaste kontrollis.
English: If you are given more Zoledronic acid Mylan than you should be If you have received doses higher than those recommended, you must be carefully monitored by your doctor.
Estonian: Kui teile manustatakse Zoledronic acid Mylan'i rohkem kui ette nähtud Kui te olete saanud soovitatust suuremaid annuseid, peab arst teid hoolega jälgima.
English: Acute renal failure, haematuria, proteinuria Acquired Fanconi syndrome
Estonian: Äge neerupuudulikkus, hematuuria, proteinuuria Omandatud Fanconi sündroom
English: - Anti-angiogenic medicines (used to treat cancer), since the combination of these with zoledronic acid has been associated with an increased risk of osteonecrosis of the jaw (ONJ).
Estonian: Antiangiogeenseid ravimeid (kasutatakse vähi ravimiseks), kuna nende kombinatsiooni zoledroonhappega on seostatud suurenenud lõualuu osteonekroosi (LON) tekke riskiga.
English: - Cancer, co morbid conditions (e.g. anaemia, coagulopathies, infection), smoking.
Estonian: Vähktõbi, kaasuvad haigused (nt aneemia, koagulopaatiad, infektsioon), suitsetamine.
English: How to store Zoledronic acid Mylan Your doctor, pharmacist or nurse knows how to store Zoledronic acid Mylan properly.
Estonian: Kuidas Zoledronic acid Mylan'i säilitada Teie raviarst, apteeker ja meditsiiniõde teavad, kuidas Zoledronic acid Mylan'i õigesti säilitada.
English: In paediatric patients with severe osteogenesis imperfecta, zoledronic acid seems to be associated with more pronounced risks for acute phase reaction, hypocalcaemia and unexplained tachycardia, in comparison to pamidronate, but this difference declined after subsequent infusions.
Estonian: Raske osteogenesis imperfecta'ga lastel tundub zoledroonhape olevat seotud enam väljendunud riskiga ägeda faasi reaktsiooni, hüpokaltseemia ja ebaselge põhjusega tahhükardia tekkeks võrreldes pamidronaadiga, aga see erinevus vähenes pärast järgnevat infusiooni.
English: Osteonecrosis has also very rarely been seen occurring with other bones than the jaw, especially the hip or thigh.
Estonian: - Osteonekroosi on täheldatud väga harva ka mujal kui lõualuus, eriti puusas või reies.
English: Adverse reactions, such as dizziness and somnolence, may have influence on the ability to drive or use machines, therefore caution should be exercised with the use of Zoledronic acid Mylan along with driving and operating of machinery.
Estonian: Kõrvaltoimed, nagu pearinglus ja unisus, võivad mõjutada autojuhtimise ja masinate käsitsemise võimet, seetõttu tuleb Zoledronic acid Mylan'i kasutamise ajal autojuhtimisel ja masinate käsitsemisel olla ettevaatlik.